ATRC AtriCure, Inc.

CIK 0001323885 37 ready 8-Ks latest July 23, 2026, 4:00 PM ET RSS · JSON

Activity: QUIET 0 filings / 30d vs 1 baseline

Ready 8-Ks 37

Latest filing July 23, 2026, 4:00 PM ET

Top materiality 0.85

Event mix earnings ×27 · other_material ×6 · other ×3

Sentiment 22 pos · 2 neg · 13 neu

Latest earnings reported 2026-Q1

Executive change recent →

Recent 8-K filings for ATRC

Highest-materiality recent filing

AtriCure Q2 revenue $71.4M (+74.8% YoY); aMAZE trial fails efficacy endpoint

August 4, 2021, 7:59 PM ET other material materiality 0.85 negative item 2.02 item 7.01 item 9.01

Revenue $71.4M, up 74.8% YoY (73.5% constant currency); U.S. $60.1M (+78.4%), international $11.3M (+57.9%).
Net loss per share $0.36; adjusted loss per share $0.30; adjusted EBITDA loss $2.7M.

Read filing →

July 23, 2026, 4:00 PM ET earnings materiality 0.75 positive item 2.02 item 9.01

AtriCure Q2 2026 revenue $153.6M (+12.8% YoY); net income $9.0M vs loss a year ago

Worldwide revenue $153.6M, up 12.8% YoY (12.4% constant currency); U.S. revenue $125.6M (+13.6%).
May 19, 2026, 4:21 PM ET other material materiality 0.40 neutral item 5.02 item 5.07 item 9.01 ◈ Shareholder Votes ×5

AtriCure shareholders approve share increases for 2023 Stock Incentive Plan and 2018 ESPP

Shareholders approved amendment to 2023 Stock Incentive Plan, increasing authorized shares from 4.5M to 6M.
May 6, 2026, 7:59 PM ET earnings materiality 0.70 positive item 2.02 item 9.01 ◈ Earnings Releases

AtriCure Q1 revenue $141.2M (+14.3%); corrects FY2026 guidance to rev $600-610M, adj EBITDA $80-82M

Q1 revenue $141.2M (+14.3% YoY); net income $0.1M, breakeven EPS.
May 5, 2026, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01 ◈ Earnings Releases

AtriCure Q1 2026 revenue $141.2M (+14.3%); net income $0.1M; adj. EBITDA $17.1M

Worldwide revenue $141.2M (+14.3% YoY); U.S. $116.2M (+14.9%), international $25.0M (+11.5%).
February 17, 2026, 6:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01

AtriCure Q4 revenue $140.5M (+13.1% YoY); guides FY26 revenue $600-610M

Q4 2025 revenue $140.5M (+13.1% YoY); net income $1.8M ($0.04 EPS) vs net loss $0.33 per share in Q4 2024.
January 12, 2026, 6:59 PM ET earnings materiality 0.75 positive item 1.01 item 2.02 item 2.03 item 9.01 ◈ Material Agreements

AtriCure reports preliminary Q4 revenue $140.5M (+13%), FY 2025 $534.5M (+15%); guides 2026 revenue ~$600-610M

Q4 2025 revenue $140.5M (+13% YoY); US $114.3M (+13%), intl $26.2M (+15% as reported).
October 29, 2025, 7:59 PM ET earnings materiality 0.70 positive item 2.02 item 9.01

AtriCure Q3 revenue $134.3M (+15.8% YoY); net loss narrows to $0.3M; raises FY2025 outlook

Revenue $134.3M, +15.8% YoY (+15.1% constant currency); US $109.3M (+14.5%), intl $25.0M (+22.0%).
October 29, 2025, 7:59 PM ET earnings materiality 0.70 positive item 2.02 item 9.01

AtriCure Q3 revenue +15.8% to $134.3M, net loss narrows to $0.3M; raises 2025 outlook

Revenue of $134.3M (+15.8% YoY); U.S. $109.3M (+14.5%), international $25.0M (+22.0%).
July 29, 2025, 7:59 PM ET earnings materiality 0.78 positive item 2.02 item 9.01

AtriCure Q2 revenue up 17%; net loss narrows; raises 2025 outlook

Worldwide revenue $136.1M (+17.1% YoY); U.S. $110.6M (+15.7%), Int'l $25.6M (+23.3%).
May 20, 2025, 7:59 PM ET other materiality 0.40 neutral item 5.02 item 5.07 item 9.01

AtriCure shareholders approve 1.7M share increase in 2023 Stock Incentive Plan at annual meeting

Shareholders approved amendment to 2023 Stock Incentive Plan, increasing shares from 2.8M to 4.5M.
April 29, 2025, 7:59 PM ET earnings materiality 0.65 positive item 2.02 item 9.01

AtriCure Q1 revenue $123.6M (+13.6% YoY); net loss improves to $6.7M from $13.2M

Revenue $123.6M (+13.6% YoY; +14.1% constant currency); U.S. $101.1M (+12.1%), International $22.5M (+20.8%).
March 26, 2025, 7:59 PM ET other materiality 0.10 neutral item 7.01 item 9.01

AtriCure holds 2025 Investor Day; presentation details not provided in filing excerpt

Investor Day held March 26, 2025 at Mason, OH headquarters from 1-4 p.m. ET.
February 12, 2025, 6:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01

AtriCure Q4 revenue $124.3M (+16.6% YoY); guides FY25 rev $517-527M

Q4 revenue $124.3M (+16.6%); full year revenue $465.3M (+16.5%).
January 13, 2025, 6:59 PM ET earnings materiality 0.75 positive item 2.02 item 7.01 item 9.01

AtriCure reports preliminary Q4 revenue $124.3M (+17%); guides 2025 revenue $517-527M

Preliminary Q4 2024 revenue $124.3M (+17% YoY as reported and constant currency).
October 29, 2024, 7:59 PM ET earnings materiality 0.70 positive item 2.02 item 9.01

AtriCure Q3 2024: revenue $115.9M (+17.9%), loss $0.17/sh, positive cash flow $16.3M

Worldwide revenue $115.9M, up 17.9% YoY; U.S. $95.5M (+16.8%), Intl $20.5M (+23.3%).
July 30, 2024, 7:59 PM ET earnings materiality 0.65 neutral item 2.02 item 9.01

AtriCure Q2 2024 revenue $116.3M (+15.2% YoY); net loss $0.17/share

Worldwide revenue $116.3M, up 15.2% YoY (15.4% constant currency); U.S. $95.5M (+12.5%), international $20.7M (+29.4%).
May 14, 2024, 7:59 PM ET other material materiality 0.30 neutral item 5.02 item 5.03 item 5.07 item 9.01 ◈ Shareholder Votes ×13◈ Governance Changes

AtriCure shareholders approve increase in authorized shares under 2023 Stock Incentive Plan to 2.8M

Shareholders approved amendment to 2023 Stock Incentive Plan, increasing shares from 1,000,000 to 2,800,000.
May 1, 2024, 7:59 PM ET earnings materiality 0.70 neutral item 2.02 item 9.01

AtriCure Q1 revenue $108.9M (+16.4% YoY); net loss per share $0.28

Worldwide revenue $108.9M, up 16.4% YoY (16.3% constant currency); U.S. revenue $90.2M (+15.4%), international $18.6M (+21.5%).
February 27, 2024, 6:59 PM ET other materiality 0.20 neutral item 5.02 item 9.01

AtriCure amends 8-K to add director Shlomi Nachman to two board committees

Shlomi Nachman elected to Board on Jan 4, 2024, as previously reported.
February 15, 2024, 6:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01 ◈ Earnings Releases

AtriCure Q4 revenue $106.5M (+21%), full-year adj EBITDA positive $19.4M; guides 2024 rev ~$459-466M

Q4 2023 revenue $106.5M (+21% YoY); full-year revenue $399.2M (+20.8%).
January 8, 2024, 6:59 PM ET earnings materiality 0.75 positive item 1.01 item 1.02 item 2.02 item 2.03 item 9.01 ◈ Material Agreements ×2◈ Debt Financings◈ Earnings Releases

AtriCure prelim Q4 rev $106.5M (+21% YoY); new $125M ABL credit facility

Q4 2023 preliminary revenue $106.5M (+21% YoY); full year revenue $399.2M (+21% YoY).
January 4, 2024, 6:59 PM ET leadership materiality 0.35 positive item 5.02 item 9.01 ◈ executive_change

AtriCure appoints former J&J executive Shlomi Nachman to Board of Directors

Shlomi Nachman elected to AtriCure Board effective January 4, 2024.
November 1, 2023, 7:59 PM ET earnings materiality 0.65 positive item 2.02 item 9.01 ◈ Earnings Releases

AtriCure Q3 revenue $98.3M (+18% YoY); positive adjusted EBITDA $4.7M

Worldwide revenue $98.3M, up 18.1% YoY; U.S. $81.7M (+17.1%), International $16.6M (+23.2%).
July 25, 2023, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01 ◈ Earnings Releases

AtriCure Q2 revenue $100.9M (+19.4% YoY); net loss narrows to $5.1M, adjusted EBITDA positive $8.0M

Worldwide revenue $100.9M, up 19.4% YoY; U.S. $84.9M (+19.1%), international $16.0M (+20.7%).
May 26, 2023, 7:59 PM ET other material materiality 0.40 neutral item 5.02 item 5.07 item 9.01 ◈ Shareholder Votes ×5

Shareholders approve 2023 equity plan and ESPP increase by 750K shares

2023 Stock Incentive Plan approved with 38.1M for, 2.3M against, 28K abstain.
May 2, 2023, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01

AtriCure Q1 revenue $93.5M (+25.4% YoY), net loss narrows to $6.5M, positive adj. EBITDA $1.9M

Revenue $93.5M (+25.4% YoY); US $78.2M (+25.6%), Intl $15.3M (+24.4%).
February 21, 2023, 6:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01 ◈ Earnings Releases ×3

AtriCure Q4 revenue $88M (+20.2% YoY); FY2022 revenue $330.4M (+20.4%); guides FY2023 rev $380-387M

Q4 2022 revenue $88.0M, up 20.2% YoY; U.S. revenue $73.9M (+20.7%), international $14.1M (+17.8%).
January 9, 2023, 6:59 PM ET earnings materiality 0.70 positive item 2.02 item 7.01 item 9.01 ◈ Earnings Releases

AtriCure reports Q4 2022 preliminary revenue $88M (+20% YoY); guides 2023 rev $380-387M

Q4 2022 revenue ~$88M (U.S. $73.9M, intl $14.1M), up 20% YoY.
November 1, 2022, 7:59 PM ET earnings materiality 0.75 negative item 2.02 item 9.01 ◈ Earnings Releases

AtriCure Q3 revenue $83.2M (+18.1% YoY); net loss $0.27/share; guides FY2022 rev ~$328-333M

Revenue $83.2M, up 18.1% YoY (19.8% constant currency). US revenue $69.8M (+21.3%).
August 2, 2022, 7:59 PM ET earnings materiality 0.70 neutral item 2.02 item 7.01 item 9.01

AtriCure Q2 2022 revenue $84.5M (+18.4%); net loss $0.32/share; FY guidance unchanged

Revenue $84.5M (+18.4% YoY; +19.8% constant currency); U.S. $71.3M (+18.6%), international $13.3M (+17.3%).
May 27, 2022, 7:59 PM ET other material materiality 0.35 neutral item 5.02 item 5.07 item 9.01

AtriCure shareholders approve 1.1M share increase to stock incentive plan

Shareholders approved amendment to 2014 Stock Incentive Plan increasing authorized shares from 5,250,000 to 6,350,000.
May 3, 2022, 7:59 PM ET earnings materiality 0.65 positive item 2.02 item 7.01 item 9.01

AtriCure Q1 revenue $74.6M (+25.8% YoY); guides FY22 rev $318-330M

Revenue $74.6M, up 25.8% YoY; U.S. $62.3M (+23.8%), intl $12.3M (+37.2%).
April 13, 2022, 7:59 PM ET other material materiality 0.60 positive item 7.01 item 9.01

AtriCure launches EnCompass Clamp for cardiac ablation in US

FDA 510(k) clearance for cardiac tissue ablation; features parallel closure, uniform pressure, custom RF power.
February 15, 2022, 6:59 PM ET earnings materiality 0.75 neutral item 2.02 item 9.01

AtriCure Q4 revenue $73.2M (+26.8% YoY); guides FY22 rev $315-330M

Q4 2021 revenue $73.2M (+26.8% YoY); U.S. $61.2M (+29.1%), Intl $12.0M (+16.3%).
January 10, 2022, 6:59 PM ET earnings materiality 0.65 neutral item 2.02 item 7.01 item 9.01

AtriCure reports preliminary Q4 revenue $73.2M (+27% YoY), guides FY2022 $315-330M

Q4 2021 revenue ~$73.2M (+27% YoY); U.S. $61.2M (+29%), Intl $12.0M (+16% as reported).
November 3, 2021, 7:59 PM ET earnings materiality 0.55 neutral item 2.02 item 9.01

AtriCure Q3 revenue $70.5M, +28.7% YoY; adj EPS -$0.23; FY guide reaffirmed

Revenue $70.5M, up 28.7% YoY (28.6% constant currency); U.S. $57.5M (+28.7%), intl $12.9M (+28.5%).
August 4, 2021, 7:59 PM ET other material materiality 0.85 negative item 2.02 item 7.01 item 9.01

AtriCure Q2 revenue $71.4M (+74.8% YoY); aMAZE trial fails efficacy endpoint

Revenue $71.4M, up 74.8% YoY (73.5% constant currency); U.S. $60.1M (+78.4%), international $11.3M (+57.9%).

Executive changes

Appointed

Shlomi Nachman

director

ATRC · AtriCure, Inc.

Effective: 2024-01-04
Filed: January 4, 2024, 6:59 PM ET

elected Shlomi Nachman to serve as a director until the next Annual Meeting of Stockholders.

Earnings & guidance

2026-Q1 EPS reported $0.00 filing →

Materiality & sentiment trend

Max materiality 0.85 · Median 0.70 · Most common event earnings

22 positive 2 negative 13 neutral

source · ATRC on sec.gov